An Open-Label, Multicenter, Phase I Study of AXT-1003 as a Single Agent in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Latest Information Update: 23 Oct 2024
At a glance
- Drugs AXT 1003 (Primary)
- Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Axter Therapeutics
Most Recent Events
- 25 Jul 2024 Status changed from recruiting to discontinued due to the adjustment of the protocol and expansion of the indication population, a new clinical trial protocol was submitted to the Health Authority, so the registration was conducted as a new clinical trial and this trial was terminated.
- 11 Aug 2023 Status changed from not yet recruiting to recruiting.
- 08 Aug 2023 New trial record